| TOTAL: $11M | ||||
| Year to Date: $137.23M | ||||
Company | Partner | Amt. | Triggering | Details (Date) |
Idenix | Novartis Pharma AG | ND | Milestone payment | Idenix received the milestone payment after the European Commission approved Sebivo for chronic hepatitis B (4/30) |
MediVas LLC* | Merck & Co. Inc. | ND | Milestone payment | MediVas achieved the milestone based on one of its orally available biologics that is the focus of the collaboration (4/3) |
Montigen | SuperGen Inc. (SUPG) | $10 | Milestone payment | FDA clearance for the start of a Phase I trial of MP470 for cancer triggered the payment to shareholders of Montigen, which SuperGen acquired in January 2006 (4/27) |
Pharmacopeia | Schering-Plough | $1 | Milestone payment | Pharmacopeia earned a $1M milestone payment for the advancement of a compound into preclinical development (4/17) |
| Notes: | ||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
| * Private company. | ||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||
| ND = Not disclosed. | ||||